Livalo generic
Livalo is an anti-hyperlipidemic drug owned by Kowa Co. This drug contains the active ingredient pitavastatin calcium and was first authorized for market use on 03 August, 2009. Livalo has a total of 4 drug patents, none of which have expired till date.
When will Livalo generic be available?
The generic versions of Livalo are expected to be released after 19 August, 2024. This is anticipated based on the expiry of the last patent on that date. The releases may also be due to Para IV filings where generic manufacturers challenge the validity of the existing patents.
Livalo uses
Livalo is used as an adjunctive therapy to diet for reducing elevated total cholesterol, low-density lipoprotein cholesterol, apolipoprotein B, and triglycerides while increasing the HDL-C in adult patients diagnosed with primary hyperlipidemia or mixed dyslipidemia. The active ingredient, pitavastatin calcium, plays a crucial role in managing these conditions.
Livalo patent expiration
Livalo owns four patents in total, with the last one expected to expire on 19 August, 2024. Post this date, the Livalo generic is likely to be released. Below are the details of the patent: